Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1855]

Latest concepts in frontline therapy for paediatric ALL

Dr Ching-Hon Pui - St Jude's Children's Research Hospital, Memphis, USA

Latest concepts in frontline therapy for paediatric ALL ( Dr Ching-Hon Pui - St Jude's Children's Research Hospital, Memphis, USA )

Professional safety for oncology nurses

Nellie Kumaralingam - The Royal Marsden NHS Foundation Trust, London, UK

Professional safety for oncology nurses ( Nellie Kumaralingam - The Royal Marsden NHS Foundation Trust, London, UK )

Are remissions for AML patients 'better' after daunorubicin and cytarabine...

Prof Daniel Ryan - University of Rochester, Rochester, USA

Are remissions for AML patients 'better' after daunorubicin and cytarabine liposome injection ( Prof Daniel Ryan - University of Rochester, Rochester, USA )

Is enasidenib plus azacitidine better than with azacitidine alone for AML...

Dr Courtney DiNardo - MD Anderson Cancer Center, Houston, USA

Is enasidenib plus azacitidine better than with azacitidine alone for AML patients? ( Dr Courtney DiNardo - MD Anderson Cancer Center, Houston, USA )

PET-Directed therapy for early-stage diffuse large B-cell lymphoma

Prof Daniel Persky - University of Arizona Cancer Center, Tucson, USA

PET-Directed therapy for early-stage diffuse large B-cell lymphoma ( Prof Daniel Persky - University of Arizona Cancer Center, Tucson, USA )

Clinical outcomes of patients with FLT3-ITD-mutated R/R AML undergoing HSCT...

Dr Siddhartha Ganguly - The University of Kansas Health System, Kansas City, USA

Clinical outcomes of patients with FLT3-ITD-mutated R/R AML undergoing HSCT after quizartinib or salvage chemo ( Dr Siddhartha Ganguly - The University of Kansas Health System, Kansas City, USA )

Outcomes in patients with therapy-Related AML who achieved remission with CPX...

Dr Jeffrey Lancet - H. Lee Moffitt Cancer Center & Research Institute, Tampa...

Outcomes in patients with therapy-Related AML who achieved remission with CPX-351 versus 7 plus 3: Phase 3 exploratory analysis ( Dr Jeffrey Lancet - H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA )

SABCS 2019 highlights

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

SABCS 2019 highlights ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )

The PEARL study: Palbociclib and endocrine therapy vs capecitabine in HR /HER2...

Dr Miguel Martín - Universidad Complutense de Madrid, Madrid, Spain

The PEARL study: Palbociclib and endocrine therapy vs capecitabine in HR /HER2- metastatic breast cancer ( Dr Miguel Martín - Universidad Complutense de Madrid, Madrid, Spain )

Exploring adjuvant endocrine therapy use with letrozole in postmenopausal women...

Dr Terry Mamounas - Orlando Health UF Health Cancer Center, Orlando, USA

Exploring adjuvant endocrine therapy use with letrozole in postmenopausal women with hormone receptor-positive breast cancer ( Dr Terry Mamounas - Orlando Health UF Health Cancer Center, Orlando, USA )

KEYNOTE-522: Neoadjuvant pembro chemo vs placebo chemo, followed by...

Dr Jay Andersen - Compass Oncology West Cancer Center, Tigard, USA

KEYNOTE-522: Neoadjuvant pembro chemo vs placebo chemo, followed by adjuvant pembro vs placebo for early TNBC ( Dr Jay Andersen - Compass Oncology West Cancer Center, Tigard, USA )

Residual cancer burden after neoadjuvant therapy and long-term survival...

Prof William Symmans - MD Anderson Cancer Center, Houston, Texas

Residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer ( Prof William Symmans - MD Anderson Cancer Center, Houston, Texas )

More from ecancer